Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for pediatric compulsivity in obsessive-compulsive disorder and autism spectrum disorder
NL-OMON41943Phase 3Active, not recruiting
- Sponsor
- Radboudumc
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) and Autism Spectrum Disorder (ASD) comparing Memantine with Placebo (2 arms). Primary endpoints: Baseline-to-endpoint change in compulsivity symptoms and Adverse event rates and profile. Started Jan 2017; status: active, not recruiting.
02
Drugs
memantine
03
Conditions
obsessive compulsive disorder (OCD)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NL-OMON41943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41943.